HONG KONG, Jan. 12, 2011 /PRNewswire-Asia/ --
As the leading provider of marketing, promotion and sales services for prescription drugs in China, China Medical System Holdings Ltd., ("CMS", HKEx Stock Code: 867) will announce its annual results for the year ended 31 December 2010 in early March 2011. CMS maintained rapid growth in 2010 and the unaudited sales for the year is expected to be approximately US$132.2 million, which represents a year over year growth of approximately 37% when compared to US$96.5 million in 2009. The strong sales growth was largely attributable to the continuous promotion and marketing activities for the Company's existing products.
About CMS
China Medical System Holdings Limited ("CMS", together with its subsidiaries, the "Group") is a leading provider of marketing, promotion and sales services for prescription drugs in China. The Group was established in 1995, and was listed on AIM in London (ticker: CMSH) in June 2007. The group successfully listed on the Main Board of the Stock Exchange of Hong Kong on 28th September 2010 (HKEx Stock Code: 0867), on the same day the company canceled the trading of its shares on AIM in London. CMS has the largest third-party promotion network in China in terms of hospital coverage, therapeutic focus and number of sales people. As of 31 July 2010, CMS has over 950 staff in its marketing, promotion and sales team, reaches close to 6,000 hospitals located across 30 provinces and over 100,000 target physicians in China, and at the present, CMS is marketing 9 main products in China which cover several therapeutic areas including the neurology, psychiatry, hepatology, gastroenterology, infectious diseases, urology, ophthalmology, cardiovascular disease, pediatrics and oncology. With deep insight and understanding of the Chinese pharmaceutical market, available treatment options, patient demography and potential competitive advantages of drugs, CMS will continue to focus on new product introduction and expand its sales network to consolidate and promote its leading position in the pharmaceutical services market in China.
Safe Harbor Statement
The statement in this news release, other than the historical financial information, may contain forward-looking statements that involve risks anduncertainties that could cause actual results to differ from anticipated results. Further information on risk factor that could affect, among other things is detailed in CMS's IPO prospectus, as filed with the Stock Exchange of Hong Kong Limited.
Please browse the link below for further information:
http://en.cms.net.cn/CMSENWEB/News%20Center/GongSiXinWen.aspx?fp_id=343
To learn more about the Company, please visit the Company's website at:
For further enquiries, please contact Hill and Knowlton Asia Ltd.:
James Wong
Tel: +852-2894-6216
Email: james.wong@hillandknowlton.com.hk
